• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » 3M, MIT working on paper-based, rapid COVID-19 test

3M, MIT working on paper-based, rapid COVID-19 test

July 14, 2020 By Nancy Crotti

The 3M COVID-19 test team works at at the pilot lab facility at 3M’s Minnesota headquarters. (Image courtesy of 3M)

3M (NYSE:MMM) announced today that it is working with Massachusetts Institute of Technology (MIT) researchers to develop a paper-based, rapid test to detect the virus that causes COVID-19, with the potential to manufacture millions of tests per day.

The test would detect viral antigens and deliver “highly accurate results within minutes” via a paper-based device, according to the Maplewood, Minn.-based company. It could be administered at the point-of-care and would not need to be sent to labs for testing.

The National Institutes of Health (NIH) selected the rapid COVID-19 test for accelerated development and commercialization support, after review by an expert panel, 3M added. Researchers received $500,000 in validation funding from the Rapid Acceleration of Diagnostics Tech (RADx Tech) program, an aggressively-paced COVID-19 diagnostics initiative from the NIH’s National Institute of Biomedical Imaging and Bioengineering.

Researchers are also working to determine whether the test is feasible to mass manufacture. The 3M team is led by scientists, manufacturing and regulatory experts from its corporate research laboratories and health care business group. The MIT team is led by Hadley Sikes of the college’s Department of Chemical Engineering.

“We are excited to collaborate with Professor Hadley Sikes and the team at MIT. Our approach is ambitious, but our collective expertise can make a difference for people around the world, so we owe it to ourselves and society to give it our best effort,” said 3M CTO John Banovetz in a news release. “We are seeking to improve the speed, accessibility and affordability of testing for the virus, a major step in helping to prevent its spread.”

Working with 3M and the NIH has greatly enhanced efforts toward swift detection of the virus, and a potential tool to help mitigate and contain the public health crisis, according to Sikes.

“There is a pressing need for a highly scalable rapid test,” she said. “We are working with our colleagues at 3M to overcome the challenges to move this research from lab to impact, and find an innovative path forward to manufacture it at scale. ”

RADx Tech’s phased innovation is initially supporting a 4-week period of intense research to demonstrate the test concept works and can be commercialized on a large scale. The project is eligible for further funding from the government program, according to 3M.

Filed Under: Business/Financial News, Diagnostics, Featured, Research & Development Tagged With: 3m, coronavirus, COVID-19, Massachusetts Institute of Technology, mit, National Institutes of Health (NIH)

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy